This position statement is aimed at front-line clinical practitioners and public health authorities in WHO European Region providing services for people wishing to reduce their risk of acquiring sexually transmitted infections (STIs), including HIV.
WernerRNSchmidtAJPotthoffAGerman and STI Society DSTIG, et al.Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy-PEP, Doxy-PrEP). J Dtsch Dermatol Ges2024; 22(3): 466–478. DOI: 10.1111/ddg.15282.
2.
BachmannLHBarbeeLAChanP, et al.CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep (Morb Mortal Wkly Rep)2024; 73(RR-2): 1–8. DOI: 10.15585/mmwr.rr7302a1.
3.
LuetkemeyerAFDonnellDDombrowskiJCDoxyPEP Study Team, et al.Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med2023; 388: 1296–1306.
4.
MolinaJ-MCharreauIChidiacCANRS IPERGAY Study Group, et al.Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis2018; 18: 308–317.
5.
MolinaJ-MBercotBAssoumouLANRS 174 DOXYVAC Study Group, et al.Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024; Published: May 23: S1473. DOI: 10.1016/S1473-3099(24)00236-6.
6.
UnemoMColeMJKodmonCEuropean Gonococcal Tetracycline-Resistance Study Group, et al.High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhoea cases?Lancet Reg Health Eur2024; 38: 100871.
7.
StewartJOwareKDonnellDdPEP Kenya Study Team, et al.Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med2023; 389: 2331–2340.
RosterKIOGradYH. Estimating changes in antibiotic consumption in the USA with the introduction of doxycycline post-exposure prophylaxis. Lancet Microbe2024; 5: e9.
10.
MortimerTDGradYH. A genomic perspective on the near-term impact of doxycycline post-exposure prophylaxis on Neisseria gonorrhoeae antimicrobial resistance. Clin Infect Dis2023; 77: 788–791.
11.
MårdhOPlachourasD. Using doxycycline for prophylaxis of bacterial sexually transmitted infections: considerations for the European Union and European Economic Area. Euro Surveill2023; 28: 2300621.
12.
KongFYSKenyonCUnemoM. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J Antimicrob Chemother2023; 78: 1561–1568. DOI: 10.1093/jac/dkad129.
